With more than 55 people dying in China of cancer every ten minutes, the country is innovating treatments and pushing to close deep gaps in fundamental care to meet its oncology crisis. Compared with the United States, the death rate from cancer in China is high and oncologists are in short supply. But new China biotechs are fueling progress in the field, cell therapy clinical trials are proliferating, and money is being funneled into boosting both the quantity and quality of research and development. In addition, local governments and pharmaceutical companies are developing early screening programs for some cancers and improving patient access to oncology care. The push, experts say, is slowly leading to improvement for patients and opportunities for manufacturers.
